Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Amneal Pharmaceuticals by 6.2%, owning approximately 15.76 million shares valued at $132 million.
• Research analysts have set a consensus target price of $11.60 for Amneal Pharmaceuticals, with five analysts rating the stock as a "Buy."
• Insider selling was observed, with executives Jason B. Daly and Andrew S. Boyer selling a total of 55,436 shares, indicating a potential decrease in insider confidence.

Vanguard Group Inc. raised its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 6.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 15,762,727 shares of the company's stock after purchasing an additional 920,758 shares during the period. Vanguard Group Inc. owned about 5.09% of Amneal Pharmaceuticals worth $132,092,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its stake in shares of Amneal Pharmaceuticals by 5.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock valued at $39,531,000 after acquiring an additional 278,653 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 37.3% during the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock valued at $29,031,000 after acquiring an additional 995,586 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Amneal Pharmaceuticals by 9.7% during the fourth quarter. Northern Trust Corp now owns 1,777,283 shares of the company's stock valued at $14,076,000 after acquiring an additional 156,699 shares during the last quarter. Phocas Financial Corp. boosted its stake in shares of Amneal Pharmaceuticals by 31.1% during the fourth quarter. Phocas Financial Corp. now owns 1,330,413 shares of the company's stock valued at $10,537,000 after acquiring an additional 315,223 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Amneal Pharmaceuticals by 7.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 819,736 shares of the company's stock worth $6,869,000 after buying an additional 59,267 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on AMRX shares. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price target on the stock. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $11.60.

Amneal Pharmaceuticals Trading Down 0.4%

Shares of Amneal Pharmaceuticals stock traded down $0.04 during trading hours on Wednesday, reaching $9.35. The stock had a trading volume of 76,034 shares, compared to its average volume of 1,671,992. The firm has a market capitalization of $2.94 billion, a price-to-earnings ratio of 940.44 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $9.79. The firm has a 50 day simple moving average of $8.43 and a two-hundred day simple moving average of $8.03.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 6,340 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $9.50, for a total transaction of $60,230.00. Following the completion of the sale, the executive vice president owned 146,403 shares in the company, valued at $1,390,828.50. This trade represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jason B. Daly sold 22,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the sale, the executive vice president owned 10,606 shares of the company's stock, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 577,206 shares of company stock worth $5,405,265 in the last 90 days. 17.45% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.